Search 

SYNthesis Research is a research “venture partner” that draws upon a deep well of experience in small molecule drug discovery, to partner with the outstanding biology of our collaborators to develop and mature new drug candidates for a broad range of therapeutic applications.

As well as developing our own pipeline of early-stage projects, SYNthesis Research has developed partnerships with the Walter and Eliza Hall Institute for Medical Research, and the Cancer Therapeutics Co-operative Research Centre (CTx-CRC), inter alia.

SYNthesis Research brings management, expertise and financing to the table, and our sister company, SYNthesis med chem, brings a chemistry-focussed contract research service to our collaborations, providing custom synthesis, medicinal chemistry and fully integrated drug discovery capabilities that delivers cost effective high quality drug discovery and development capability.

We are seeking innovation partners for shared risk, in-licensing and partnering.

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.